REGENERON Pharmaceuticals Inc's antibody cocktail therapy for COVID-19 will likely also be effective against the new variants of the virus, the drugmaker's chief executive officer has said. Regeneron's antibody therapy received U.S. Food and Drug Administration's authorization for emergency use in mild to moderate COVID-19 patients in November. "We do believe cocktail is very important... having a cocktail makes it more likely we will be able to deal with variants that might pop up," Chief Executive Officer Leonard Schleifer said during J.P. Morgan Health Conference. Regeneron said its cocktail approach has resulted in a treatment that should work against the…